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Introduction: Mutations of the epidermal growth factor receptor
(EGFR) have been proven to predict activity of the EGFR-tyrosine
kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the
“common” EGFR mutations, such as the L858R point mutation in
exon 21 and the in-frame deletional mutation in exon 19, have been
definitively associated with response to EGFR-TKIs, the correlation
with response to treatment for many other rarer mutations is still
unclear. In this study, we report the results of treating patients with
advanced non-small cell lung cancer harboring rare EGFRmutations
treated with EGFR-TKIs.
Methods: The frequency of rare mutations has been investigated in
681 cases of non-small cell lung cancer screened between 2006 and
2010. Mutations in exons 18 and 20, uncommon mutations in exons
19 and 21, and/or the presence of different mutations in a single
tumor (complex mutations) were considered rare.
Results: EGFR mutations were detected in 99 tumors (14.5%).
Eighteen cases carried rare mutations, and 10 of these patients were
treated with erlotinib or gefitinib. The clinical outcome was de-
scribed case by case with references to the literature. Of note, we
found two EGFR mutations never identified before and one of
unknown response to EGFR-TKIs.
Conclusions: Gefitinib and erlotinib have different antitumor activ-
ity according to the type of the EGFR mutation borne. Report of
cases harboring rare mutations can support the decision-making
process in this subset of patients.
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In the past 5 years, the epidermal growth factor receptor(EGFR) inhibitors gefitinib (Iressa; Astra Zeneca) and er-
lotinib (Tarceva; Roche) have shown their efficacy in the
treatment of a subset of non-small cell lung cancers
(NSCLCs) harboring EGFR mutations.1–3 The frequency of
EGFR mutations depends on the population studied.4 In
North America and Western Europe, approximately 10% of
cases harbor mutations, whereas in individuals of East Asian
origin approximately 30 to 50% have a mutation. These
mutations are strongly associated with the female sex, a
history of never smoking, and adenocarcinoma histology,
mainly with bronchioloalveolar carcinoma (BAC) subtype.5
In normal cells, the EGFR is only activated on binding
of the cognate ligand to the receptor, however, in tumor cells
carrying a mutation in the adenosine triphosphate (ATP)-
binding pocket of the kinase domain (exons 18–21) of the
EGFR, the receptor is constitutively activated. It has been
postulated that these mutations cause structural alterations
that destabilize the autoinhibited conformation of the receptor
normally assumed in the absence of ligand binding.6,7 As a
consequence of improper activation, tumor cells acquire a
malignant phenotype characterized by abnormal cell survival
and proliferation.
The small molecules gefitinib and erlotinib inhibit
EGFR activity by competing with ATP for the binding to the
kinase domain. Moreover, in contrast to the wild-type EGFR,
the presence of activating mutations results in preferential
binding of gefitinib and erlotinib versus ATP. The response
rate to gefitinib and erlotinib is nearly 75% in patients with
tumors harboring EGFR mutations.4,8 Nevertheless, there are
some patients with mutations of EGFR that do not respond to
tyrosine kinase inhibitors (TKIs). Indeed, although the “com-
mon” EGFR mutations, such as the L858R point mutation in
exon 21 and the in-frame deletional mutation in exon 19,
have been definitively associated with response to EGFR-
TKIs, many other EGFR mutations are only occasionally
detected in patients with NSCLC, and data on their correla-
tion with response to EGFR-TKIs are still unclear. In vitro
model systems, for example, have shown that exon 20 mu-
tations render transformed cells less responsive to EGFR-
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TKIs.9 Nevertheless, mutations in exon 20 are relatively rare,
suggesting that other mechanisms probably contribute to
EGFR-TKI primary resistance in metastatic NSCLC. For
many of the rare mutations, the effect on responsiveness
remains unknown. Thus, it is of extreme importance for the
clinical decision-making process to share information of
patients harboring such mutations, particularly when the
outcome of EGFR-TKI treatment is available.
We report herein our single institute’s experience in the
treatment of patients with rare EGFR mutations. Mutations in
exons 18 and 20, uncommon mutations in exons 19 and 21,
and/or the presence of different mutations in a single tumor
(complex mutations) were all considered rare. From 2006 to
2010, we screened 681 cases of NSCLC for EGFR mutations
and found 18 cases with rare mutations. Ten of these patients
were treated with gefitinib or erlotinib, and we discuss their
clinical outcome case by case with references to the literature,
if available. Of note, two novel mutations were identified and
in a third case, this is the first report of EGFR-TKI efficacy
with such a mutation. The other mutations have been previ-
ously described in only a handful of case reports.
MATERIALS AND METHODS
Sample Collection and EGFR Mutation Analysis
EGFR mutational analyses were performed in 681
patients who underwent curative surgery or surgical biopsy
between 2006 and 2010 at the European Institute of Oncol-
ogy, Milan, Italy. All the patients were Caucasian, and none
had received any EGFR-TKI before DNA sequencing. Each
patient signed a written informed consent for the use of tissue
for molecular analysis.
Rare mutations were defined as mutations in exons 18
and 20, unusual ones occurring in exons 19 and 21, and/or
complex mutations (different mutations co-occurring within
the same tumor).
Microscopically guided dissections were performed by
a pathologist in 545 of the 681 cases analyzed (80%). The
percentage of tumor content was above 50 in all the cases.
Cases with lower tumor content were excluded from this
series. All the mutations, mainly the rare or “new mutations”
(never reported in the Catalogue of Somatic Mutations in
Cancer Database, www.sanger.ac.uk/genetics/CGP/cosmic/)
were confirmed by a further analysis of the same specimen.
To avoid misclassifying unusual sequence patterns induced
by formalin fixation artifacts as rare or novel mutations, we
repeated the polymerase chain reactions using a larger
amount of template DNA (upto 1 g of DNA recovered from
the specimen). These errors can be due to postmortem deami-
nation of cytosine or adenine, resulting in uracil or hypoxan-
thine residues, respectively. These small alterations can be
amplified from very low concentrations of tumor DNA,
whereas when the deaminated sites are diluted in larger
amount of template, they are not detected.10–12
After macrodissection, DNA was extracted using
QIAamp DNA FFPE Tissue kit (Qiagen, Hiden, Germany).
Briefly, 200 ng of DNA, quantified using Nanodrop (Thermo
scientific, Waltham, MA), were used to amplify exons 18–
19-20–21 of the EGFR. All the polymerase chain reaction
products were analyzed on a 2% agarose gel, stained with
ethidium bromide and then purified by enzyme treatment with
Exonuclease I and Shrimp Alkaline Phosphatase (SAP) be-
fore the sequencing reaction (USB, Cleveland, OH). The
cycle sequencing reactions were carried out using Big Dye
chemistry (Applied Biosystems, Foster City, CA) according
to the manufacture’s guidelines. Removal of unincorporated
deoxinucleotide triphosphate was carried out with the Se-
quencing Reaction Cleanup Kit (Millipore, Billerica, MA).
Sequencing fragments were detected by capillary electropho-
resis using the ABI Prism 3100 analyzer. Sequence chro-
matograms were analyzed by SeqScape v2.5 software (Ap-
plied Biosystems).
Evaluation of EGFR-TKI Efficacy
Ten of the 18 patients harboring rare mutations were
treated with gefitinib or erlotinib. The patients’ characteristics
are summarized in Table 1. Gefitinib was taken orally at the
dose of 250 mg daily, and erlotinib was taken at the dose of
150 mg daily, until tumor progression, death, or patient
refusal. All patients had a pretreatment tumor assessment by
TABLE 1. Patients Characteristics and Response to EGFR-TKI
Age (yr) Sex His Smoking Treatment Response PFS (mo) Mutation
80 F adk Never Erlotinib PR 12 E709A  G719C
50 F adk Never Erlotinib PRa 4 G719S
36 F adk Former Erlotinib PR 7 del I744_K745insKIPVAI
55 M undiff. Current Erlotinib PD 2.5 S784F
72 F adk Unknown Gefitinib PD 3 S768_V769insVAS
55 F adk Never Gefitinib PD 1 770_771insVDSVDNP
34 F adk Never Erlotinib PD 2 L861R
57 F adk Former Erlotinib PD 3 L861Q
54 M adk Current Gefitinib PD 2 L862V
56 F adk Never Erlotinib SDb 5 L858R  H870R
a Overall partial response but progression at a single lymph node station and at bone metastases.
b Non-RECIST response followed by rapid tumor progression.
His, histology; adk, adenocarcinoma; undiff, undifferentiated NSCLC; PR, partial response; SD, stable disease; PD, progressive disease;
PFS, progression-free survival; del, deletional mutation; ins, insertion; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor;
NSCLC, non-small cell lung cancer.
De Pas et al. Journal of Thoracic Oncology • Volume 6, Number 11, November 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1896
computer tomography scan, which was repeated to assess
tumor response after a maximum of 12 weeks from the
beginning of the treatment, then every 3 to 4 months until
treatment discontinuation. Tumor Response was evaluated
using RECIST.13 The duration of progression-free survival
was calculated from the date of treatment initiation to the date
of disease progression or death.
An informed written consent was obtained from all the
patients.
RESULTS
Frequency of EGFR Mutations
EGFR mutations were detected in 99 of 681 patients
(14.5%): 58 females and 41 males. Only tumors with adeno-
carcinoma histology carried mutations of the EGFR.
“Classic” mutations in the exons 19 (in-frame deletion)
and 21 (point mutation L858R) were found in 81 cases (81.8%).
Rare mutations, defined as mutations in exons 18 and
20, uncommon mutations in exons 19 and 21, and/or complex
mutations were identified in 18 tumors corresponding to 2.6%
of the entire population analyzed.
In Table 2, the results of Sanger sequencing are listed in
detail.
Response to EGFR-TKI in Patients with Rare
Mutations
Exon 18 Mutations
E 709AG719C
Case report. The E709AG719C double mutation was
found in an 80-year-old female never smoker with advanced
adenocarcinoma of the lung with acinar and BAC character-
istics. Other molecular features were absence of EGFR am-
plification, high EGFR chromosome 7 polysomy,14 and ab-
sence of K-Ras mutations (codon 12, 13 e 61).
After pulmonary and mediastinal tumor progression, the
patient was treated with single-line monochemotherapy
(weekly intravenous vinorelbine), which was interrupted
early due to toxicity. Erlotinib was subsequently given at the
starting dose of 150 mg daily, reduced to 100 and 75 mg due
to G3 skin toxicity. The tumor assessment, performed 2
months after the beginning of the treatment, showed a partial
response (PR), still maintained after 10 months.
Review of the literature. The complex mutation has been
previously described in a few reports. In vitro data suggest
that the coexistence of the E709A mutation confers resistance
to the gefitinib-sensitive G719C mutation.15 Nevertheless, the
low sensitivity to EGFR-TKIs of the double mutant has not
been confirmed by Hijiya et al.16 Indeed, in the single case
reported by these authors, a female never smoker of Asian
origin, with an adenocarcinoma of the lung, had a major
tumor response on treatment with gefitinib.
Conclusion. According to the cases described so far, the
E709AG719C complex mutation seems to be associated
with sensitivity to EGFR-TKI.
G719S
Case report. The G719S mutation was found in a 50-year-
old female never smoker with advanced adenocarcinoma of
the lung. Other molecular features were absence of EGFR
amplification, low EGFR chromosome 7 trisomy,14 and ab-
sence of K-Ras mutations (codon 12, 13 e 61).
Initially, the patient underwent six cycles of cisplatin and
gemcitabine with minimal tumor response for locally ad-
vanced disease. One month after the end of chemotherapy,
because of the appearance of brain and bone metastases, she
started erlotinib at 150 mg/d. At the first computer tomogra-
phy scan evaluation, performed 2 months later, disease re-
duction of multiple primary lung and nodal lesions was
evident. Brain metastases were stable. Only a single medias-
tinal lymph node and the acetabular bone metastases (already
subjected to radiotherapy) were increased in dimension. The
patient is still on treatment after 4 months.
Review of the literature. In vitro studies suggest that the
EGFR-G719S mutation is oncogenic but is significantly less
sensitive to gefitinib than the more common L858R.17 Three
patients, all of Asian origin, have been reported with the
G719S mutation: two patients showed no tumor response to
gefitinib treatment, whereas only one had a PR.18,19
TABLE 2. Genomic Alterations in the Tyrosine Kinase
Domain (Exons 18–21) of the EGFR Gene
Mutations in exon 18
4/99 cases
2 with G719S
1 with G719A  L831R
1 with G709A  G719C
Mutation in exon 19
57/99 cases
52 in-frame deletions
4 in-frame deletions with insertion
I744_K745insKIPVAI
I747_755insAT
E746_A750 S
E746_A750 Q
1 in-frame deletion with K-ras mut
K746_A750  G12V
Mutation in exon 20
3/99 cases
2 with insertions
S768_V769insVAS
770_771insVDSVDNP
Mutation in exon 21
35/99 cases
29 with L858R
1 with L861R
1 with L861Q
1 with L862V
1 with L858R  H870R
1 with L833V  H835L
1 with L831R  G719A
EGFR, epidermal growth factor receptor.
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Conclusion. In the literature, the G719S is not associated
with a clear resistance to EGFR-TKIs, as suggested by in
vitro data. Notably, in our experience, the patient had an
overall major tumor response but progressed at a single
lymph node station and at the bone level.
Exon 19 Mutations
del I744_K745insKIPVAI
Case report. The del I744_K745insKIPVAI mutation was
found in a 36-year-old former female smoker, with an ade-
nocarcinoma of the lung. Other molecular features included
the presence of EGFR amplification (fluorescence in situ
hybridization), high EGFR chromosome 7 polysomy,14 and
absence of K-Ras mutations (codon 12, 13 e 61).
At diagnosis, the patient also had synchronous metastases
in lungs, liver, and bone. The patient was treated as first-line
chemotherapy with carboplatinum and paclitaxel combined
with a vascular disrupting agent/placebo (double-blinded ran-
domized phase III study) for four cycles with liver, brain, and
lung disease progression. After a whole brain radiation, she
received erlotinib at a 150 mg daily dose. A clinical mean-
ingful improvement of symptoms was obtained within a few
days, and a tumor assessment after 8 weeks showed a PR.
After 7 months, the patient experienced disease progression
and died 2 months after treatment interruption.
Review of the literature. The presence of the del
I744_K745insKIPVAI has already been reported in Asian
and Caucasian patients by Kosaka et al.,20 Okami et al.,21 and
Ilie et al.,22 but no information on the efficacy of EGFR-TKI
is mentioned. The only evidence of treatment outcome relies
on a single case of an Asian patient treated with gefitinib. The
patient experienced tumor progression.23
Conclusion. Differently from the single case reported in
literature showing progression following gefitinib, the patient
treated in our institution had a rapid symptomatic improve-
ment and a RECIST PR.
Exon 20 Mutations
S784F
Case report. The S784F EGFR mutation was found in a
55-year-old current heavy male smoker, with pulmonary
undifferentiated NSCLC not otherwise specified. Other mo-
lecular features included absence of EGFR amplification and
absence of K-Ras mutations (codon 12, 13 e 61).
The tumor was diagnosed as stage IIIb pN3 with synchro-
nous adrenal metastasis and seemed to be refractory to the
cisplatinum and gemcitabine combination. The patient was
subsequently treated with docetaxel, interrupted early be-
cause of an allergic reaction, and then received erlotinib 150
mg/d. The patient was taken off erlotinib after 2 weeks due to
a lung infection and then started treatment again after 2
months. A tumor progression was observed after 10 weeks at
the first treatment assessment.
Review of the literature. The S784F mutation was previ-
ously described in a single patient, of the 325 analyzed by
Tsao et al.24 Nevertheless, no data dealing with EGFR-TKI
activity are reported. The same mutation has been found by
Ludovini et al.,25 but in association with the V786M in exon
20, in a never-smoking patient with an adenocarcinoma with
BAC features. In this case, the patient had a complete and
long-lasting remission after gefitinib treatment.
Conclusion. Differently from the case reported by Lu-
dovini et al. where the S784F was linked to the V786M, in
our experience the S784F EGFR mutation is associated with
resistance to erlotinib.
S768_V769insVAS
Case report. S768_V769insVAS was detected in a 72-
year-old woman with unknown smoking habits. Other mo-
lecular features were absence of EGFR amplification and
absence of K-Ras mutations (codon 12, 13 e 61).
After diagnosis of pulmonary adenocarcinoma with syn-
chronous bone metastases, the patient received gefitinib 250
mg/d upfront. Despite this treatment, she had a clinical
progression after 3 months.
Review of the literature. A number of alterations within
the EGFR S768 region, such as single nucleotide substitu-
tions, in-frame deletions, and insertions, have been observed
in a Japanese population.26 Nevertheless, no information
about the responsiveness to EGFR-TKIs was reported.
Conclusion. Herein, we describe an insertion of the S768
region, the S768_V769insVAS, in a female of Caucasian
origin. In our experience, this alteration confers resistance to
gefitinib.
770_771insVDSVDNP
Case report. The 770_771insVDSVDNP EGFR mutation
was found in a 55-year-old female never smoker with a
pulmonary adenocarcinoma. Other molecular features were
the absence of EGFR amplifications and the absence of K-Ras
mutations (codon 12, 13 e 61).
The tumor was diagnosed as stage IV with synchronous
liver, bone, and lung metastases. After a partial tumor re-
sponse obtained with a combination of carboplatinum and
paclitaxel, she received maintenance therapy with gefitinib
250 mg/d, with an immediate progressive disease (4 weeks).
The patient received further treatment with cisplatinum plus
gemcitabine, without neither clinical benefit nor tumor re-
sponse. She received third-line chemotherapy with vinorel-
bine in another institution. The patient died 3 months later.
Review of the literature. To our knowledge, the
770_771insVDSVDNP mutation has never been reported be-
fore. Other, more frequent insertions within the same region, i.e.,
D770_N771insNPG, D770insSVQ, and D770_N771insG, oc-
curring in almost 5% of NSCLC, have been widely studied.
Greulich et al.9 demonstrated in vitro that in comparison
with exon 19 deletions and with the L858R mutation,
D770_N771insNPG is insensitive to EGFR-TKI. In keeping,
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Wu et al.27 described a case of a Japanese never smoker
female with an adenocarcinoma harboring an insertion at the
D770_N771 level (D770_N771insD) who was resistant to
gefitinib.
Conclusion. Herein, we report for the first time the
770_771insVDSVDNP EGFR mutation; the patient bearing
the alteration was resistant to treatment with gefitinib.
Exon 21 Mutations
L861R
Case report. The L861R EGFR mutation was detected in
a 34-year-old female never smoker, with a pulmonary ade-
nocarcinoma with prevalent BAC characteristics. Other mo-
lecular features included the absence of EGFR amplification
and the absence of K-Ras mutations (codon 12, 13 e 61).
The tumor was diagnosed as stage IV with synchronous
liver, bone, and lung metastases. The patient received cis-
platinum, gemcitabine, and bevacizumab as front-line treat-
ment, with a partial tumor response after the first three cycles
and tumor progression after three additional cycles. She was
subsequently treated with erlotinib 150 mg/d but showed
tumor progression after 2 months and died 1 month later due
to brain and leptomeningeal progression.
Review of the literature. Data dealing with this EGFR
mutation and response to EGFR-TKI were firstly reported by
Yang et al.28 The mutation was found in a single case out of
109 NSCLCs analyzed. After gefitinib treatment, the patient
had stable disease, according to RECIST criteria, for an
unknown duration. Interestingly, in a different patient with a
lung adenocarcinoma, the L861R mutation was found coex-
isting with an EGFR germline mutation (R831C).29 After a
few months of gefitinib treatment, the patient displayed a PR.
No information about the sensitivity of R831C to gefitinib is
available.
Conclusion. Literature data28 and our experience suggest
that the L861R EGFR mutation confers resistance to gefitinib
treatment. Indeed, the only response to gefitinib observed in
the presence of the L861R reported by Chung et al. could be
attributed to the coexisting EGFR mutation, R831C.
L861Q
Case report. The L861Q EGFR mutation was detected in
a 57-year-old female former smoker with a lung adenocarci-
noma with prevalent BAC features. Other molecular features
were the absence of EGFR amplification and chromosome 7
polysomy.14 No K-Ras mutations at codons 12, 13 e 61 were
found.
The tumor was diagnosed with a multifocal omo-lobar
disease and was treated with surgery followed by adjuvant
chemotherapy (platinum and gemcitabine), which consented
2 years of disease-free survival. When the disease progressed,
the patient received erlotinib 150 mg/d, but at the first tumor
assessment (3 months), there was disease progression. The
patient subsequently received a pemetrexed and gemcitabine
combination resulting in a tumor response, followed by
vinflunine with disease progression. She was further treated
with vinorelbine and with paclitaxel in another institution,
without clinical benefit.
Review of the literature. The L861Q EGFR mutation has
been extensively investigated and is considered as one of the
major drug-sensitive mutations.30
Conclusion. In our experience, the L861Q EGFRmutation
was associated with tumor progression, despite treatment
with active doses of erlotinib and the presence of chromo-
some 7 polysomy, a positive predictive factor.
L862V
Case report. The L862V EGFR mutation was detected in
a 54-year-old male light smoker (3 packs/y) with a pulmonary
adenocarcinoma. Other molecular features were the absence
of K-Ras mutations (codon 12, 13 e 61) and EGFR amplifi-
cation. The tumor was diagnosed as stage IV with synchro-
nous brain metastasis, and the patient was treated with induc-
tion chemotherapy (carboplatinum and paclitaxel, gamma
knife on the brain lesion, and radical surgery for the primary
tumor). One year later, because of disease progression, he
received gefitinib, 250 mg/d, with further tumor progression
in 2 months.
Review of the literature. To the authors’ knowledge, this
mutation has never been previously reported.
Conclusion. This is the first description of L862V EGFR
mutation. In our experience, this alteration is associated with
gefitinib resistance.
858RH870R
Case report. The double L858R, H870R EGFR mutation
were detected in a 56-year-old male never smoker with a
pulmonary adenocarcinoma. Other molecular features were
the presence of EGFR amplification and the absence of K-Ras
mutations (codon 12, 13 e 61). The tumor was diagnosed as
stage IV with synchronous brain and bone metastases. The
patient received first-line chemotherapy with cisplatinum and
gemcitabine in another Institution and then, at the time of
progression, was started on erlotinib, 150 mg/d. At the first
tumor assessment, 2 months before the beginning of treat-
ment, a non-RECIST response was observed, but, during the
following 3 months, the disease rapidly progressed, with
brain metastases, leading to death.
Review of the literature. The L858R, H870R EGFR mu-
tation was extensively studied by Tam et al.15 In vitro
experiments demonstrated that both the single H870R and the
double L858R/H870R mutations show a higher resistance to
gefitinib compared with the single L858R mutation. More-
over, in one case of a tumor harboring the double mutation,
there was an initial response to gefitinib but leptomeningeal
metastases developed after 6 months. The authors speculate
that the cerebral disease progression could be ascribed to
dosage, suggesting that the double L858R/H870R mutation
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may require higher gefitinib administration to overcome the
brain barrier effect.
Conclusions. Notably, similar to the case reported by Tam
et al., in our experience, the L858R H870R mutation is
associated to a short-term response to gefitinib followed by
immediate and rapid tumor progression, in particular to the
brain. These finding suggest that the additional presence of
the H870R mutation could interfere with the extreme gefitinib
sensitivity of the common L858R mutation indicated by in
vitro experiments.
DISCUSSION
In this study, we report our single, institutional expe-
rience of the treatment of patients with NSCLC harboring
various rare EGFR mutations.
The overall frequency of EGFR mutations in NSCLC is
pretty high, ranging from 5 to 20%, depending on the popu-
lation studied.4 Gefitinib and erlotinib, two small molecules
that target EGFR, have proven their efficacy in the treatment
of patients with this subset of tumors, showing a response rate
of approximately 75%.4,8 The two most common mutations
that account for 90% of all cases are termed “classical”
activating mutations. One is a short in-frame deletion of exon
19 and the other a point mutation (CTG to CGG) in exon 21
at nucleotide 2573 resulting in the substitution of leucine by
arginine at codon 858 (L858R). Nevertheless, not all activat-
ing mutations necessarily cause a full blown of the EGFR
tyrosin-kinase activity. Indeed, it is widely accepted that in
NSCLC, response rates to EGFR-TKIs are higher in patients
with tumors carrying exon 19 mutations than in those with
exon 21 mutations4,31 Moreover, the T790M mutation, as
well as other point mutations, such as the D761Y (aspartic
acid-761 to tyrosine) have been reported to be strongly
associated with drug resistance probably by weakening the
interaction of EGFR-TKI with its target.32 This type of
mutation could, therefore, influence the sensitivity of the
tumor to EGFR-TKIs. Things become even more compli-
cated when rare mutations are encountered, as there is very
little information in the literature concerning the efficacy of
gefitinib and erlotinib in such cases.
For this reason, starting from an EGFR mutation
screen, performed in our institute, we selected tumors with
rare EGFR mutations and illustrated the response rate after
gefitinib or erlotinib treatment. In detail, we analyzed 681
tumors and identified 18 cases, with rare mutations, defined
as mutations in exons 18 and 20, uncommon mutations in
exons 19 and 21, and/or complex mutations (different muta-
tions present in a single tumor). These mutations accounted
for approximately 2% of all the cases screened. Ten of these
patients were treated with EGFR-TKIs, and we report herein
the individual case reports with reference to the literature.
The various tumor responses observed supported the
different predictive value of the single EGFR mutations in
terms of treatment efficacy. Of note, in our experience,
exon 20 mutations were associated with gefitinib and
erlotinib resistance; however, there are only a few reports
in the literature of cases responding to EGFR-TKIs. There-
fore, we believe that the evaluation of the single mutations
case by case could be useful also in the presence of exon
20 mutations, as in the presence of other uncommon EGFR
mutations.
In conclusion, we have provided additional information
regarding the efficacy of gefitinib and erlotinib for several
rare EGFR mutations not previously or only rarely reported
and have also identified two new mutations. We think that
this data will be useful for the treatment of patients harboring
these mutations, and we encourage the publication of similar
studies to support the decision-making process in such sub-
sets of patients.
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